122 related articles for article (PubMed ID: 11129105)
1. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Prikhojan A; Brannan T; Yahr MD
J Neural Transm (Vienna); 2000; 107(10):1159-64. PubMed ID: 11129105
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Parkinson's disease should begin with a dopamine agonist.
Montastruc JL; Rascol O; Senard JM
Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
[TBL] [Abstract][Full Text] [Related]
6. D1 dopamine receptor activity of anti-parkinsonian drugs.
Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
[TBL] [Abstract][Full Text] [Related]
7. Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Prat G; Robledo P; Rubio A; Barbanoj M; Jané F; Casas M
Brain Res; 2000 Jun; 868(2):376-9. PubMed ID: 10854593
[TBL] [Abstract][Full Text] [Related]
8. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
10. Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Tsuchioka A; Oana F; Suzuki T; Yamauchi Y; Ijiro T; Kaidoh K; Hiratochi M
Neuroreport; 2015 Dec; 26(18):1126-32. PubMed ID: 26559726
[TBL] [Abstract][Full Text] [Related]
11. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
Zhang XX; Jin GZ; Wei YF
Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):423-7. PubMed ID: 8701759
[TBL] [Abstract][Full Text] [Related]
12. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.
Wynalda MA; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1211-4. PubMed ID: 9321526
[TBL] [Abstract][Full Text] [Related]
13. D
Mailman RB; Yang Y; Huang X
Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
[TBL] [Abstract][Full Text] [Related]
14. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
15. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
Seeman P
Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
[TBL] [Abstract][Full Text] [Related]
16. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
17. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
Byrnes EM; Bruno JP
Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
[TBL] [Abstract][Full Text] [Related]
18. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonists.
Factor SA
Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
[TBL] [Abstract][Full Text] [Related]
20. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
